Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

Merck’s cancer drug Keytruda is catching up to AbbVie’s Humira as the highest selling drug in the world. Merck reported Oct. 28 that Keytruda brought in a record $4.5 billion in revenue in the third ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

The cancer immunotherapy drug Keytruda (pembrolizumab), was approved Thursday by the U.S. Food and Drug Administration (FDA) to help in the fight against renal cell carcinoma (RCC), according to a ...

Merck’s oncology drug Keytruda will outpace all Rx brands by global sales in 2028, as Roche rides its biologics stable to become the frontrunner among pharma companies, according to a five-year World ...

(Reuters) - U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling ...

The FDA granted a fast track designation to an investigational drug alone and in combination with Keytruda to treat patients with HPV recurrent/metastatic head and neck squamous cell carcinoma. The ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail. Over ...

A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors. A separate group ...

Jan 12 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in combination with ...